| Trial ID # | NCT02193633 |
| Phase | I |
| Drug Class | Signaling Pathway Inhibitors: PI3K-AKT-mTOR/TORC1/2 |
| Drug Name | Vistusertib |
| Alternate Drug Names | AZD2014 |
| Drugs in Trial | Paclitaxel, Vistusertib |
| Eligible Participant | Advanced solid tumors |
| Patients Enrolled | 70 (Expansion: 25; median 3 prior therapies) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, PFS, RP2D, evaluated per RECIST and CA125 |
| Efficacy | RP2D: 80 mg/m2/week Pac and 50 mg bid 3/7days Vis; 6/7 weeks Expansion cohort analysis (40% Pt-S/Part-Pt-S, 60% Pt-R/Pt-Rf): |
| Clinically Significant Adverse Events | Dose Limiting Toxicities: fatigue, mucositis |
| Conclusion | Promising drug combination with anti-tumor activity |
| Reference | Basu B et al. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer. Ann Oncol (2018) 29(9):1918-1925 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.